Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA by Johnson & Johnson (JNJ) seeking the first approval of icotrokinra. Icotrokinra is designed to block the IL-23 receptor, which underpins the inflammatory response in plaque PsO and offers potential in other IL-23-mediated diseases. Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist announces NDA submission by Johnson & Johnson for icotrokinra
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
- Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
- Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities